Medication info

JW Pharmaceutical Losartan Plus Tablet

Prescription medicationApproval withdrawn
Ingredient · strength
Losartan Potassium›Strength being verifiedHydrochlorothiazide›Strength being verified
Manufacturer / importer
JW Pharmaceutical Co., Ltd.
Appearance
Yellow oval film-coated tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Approval withdrawn

MFDS item code 200607677 · Notified 2006.09.28

This product's status changed to Approval withdrawn on 2023.06.20. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension not controlled by monotherapy
Who uses it
Adults · Children
Adult dosage
○ Adults The usual dose of this drug is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg daily are not recommended. The maximum blood pressure-lowering effect generally occurs around 3 weeks after starting treatment. This drug may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this drug when the expected effect is not achieved with monotherapy. 1. Substitution therapy: A dose-adjusted combination of losartan potassium and hydrochlorothiazide administered separately may be replaced with this drug. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control with this dose: Treatment may be initiated with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Administer the usual dose if creatinine clearance is 30 mL/min or higher. Use of loop diuretics rather than thiazide drugs is preferable in patients with more severe renal impairment; therefore, use in these patients is not recommended. ○ Patients with hepatic impairment The initial dose of losartan potassium for patients with hepatic impairment requiring dose adjustment is 25 mg, which cannot be administered with this drug; therefore, use in these patients is not recommended.
Children's dosage
Under 18 years: There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Manufacturer
JW Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled by monotherapy

  • Hypertension
View approved original text

This medication is used for patients with hypertension whose blood pressure is not adequately controlled with monotherapy.

Dosage and Administration

Adult dosage

○ Adults The usual dose of this drug is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg daily are not recommended. The maximum blood pressure-lowering effect generally occurs around 3 weeks after starting treatment. This drug may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this drug when the expected effect is not achieved with monotherapy. 1. Substitution therapy: A dose-adjusted combination of losartan potassium and hydrochlorothiazide administered separately may be replaced with this drug. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control with this dose: Treatment may be initiated with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Administer the usual dose if creatinine clearance is 30 mL/min or higher. Use of loop diuretics rather than thiazide drugs is preferable in patients with more severe renal impairment; therefore, use in these patients is not recommended. ○ Patients with hepatic impairment The initial dose of losartan potassium for patients with hepatic impairment requiring dose adjustment is 25 mg, which cannot be administered with this drug; therefore, use in these patients is not recommended.

Children's dosage

Under 18 years: There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately if pregnancy is confirmed. This medication should not be used by individuals with certain diseases or allergies to medications, and it should be avoided by patients with severely impaired kidney or liver function, as well as women who may become pregnant. Patients with very low blood pressure or issues with renal blood vessels and those with electrolyte imbalances should use this medication with caution, and elderly patients or those with a history of diabetes or gout should also take care. While taking this medication, various side effects such as dizziness, drowsiness, skin rash, muscle pain, and indigestion may occur, and if any abnormal symptoms appear, consultation with a physician is recommended. This medication may interact with other drugs, so it is essential to consult a healthcare professional, especially when taken with potassium supplements, diuretics, antihypertensives, lithium, or non-steroidal anti-inflammatory drugs. Pregnant or breastfeeding women should avoid taking this medication, as it may cause adverse reactions in infants. Safety in children and adolescents has not been established, so this medication should not be administered to children or adolescents. Regular blood tests and kidney function tests should be performed while on this medication to check for electrolyte imbalances or changes in kidney function, and if symptoms occur, the healthcare professionals should be notified immediately. Care should be taken when driving or operating machinery as dizziness or drowsiness may occur. This medication should be kept out of the reach of children and stored in its original container to prevent misuse or deterioration in quality.

Side effects

  • Craniosynostosis
  • anuria
  • hypotension
  • renal failure
  • death
  • abdominal pain
  • edema
  • palpitations
  • back pain
  • dizziness
Show 126 more
  • cough
  • sinusitis
  • upper respiratory infection
  • rash
  • angioedema
  • skin peeling
  • hemolysis
  • chest pain
  • facial edema
  • fever
  • orthostatic hypotension
  • syncope
  • angina
  • arrhythmia
  • cerebrovascular accident
  • myocardial infarction
  • secondary atrioventricular block
  • anorexia
  • constipation
  • toothache
  • dry mouth
  • dyspepsia
  • flatulence
  • gastritis
  • vomiting
  • malaise
  • anemia
  • gout
  • arm pain
  • arthralgia
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • leg pain
  • muscle cramps
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscular rigidity
  • anxiety
  • anxiety disorder
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory loss
  • insomnia
  • decreased libido
  • memory impairment
  • migraine
  • neuralgia
  • panic disorder
  • sensory abnormalities
  • peripheral neuropathy
  • sleep disorder
  • drowsiness
  • tremor
  • dyspnea
  • epistaxis
  • nasal congestion
  • pharyngeal discomfort
  • respiratory congestion
  • rhinitis
  • venous sinus disorder
  • chest discomfort
  • alopecia
  • dermatitis
  • dry skin
  • petechiae
  • erythema
  • flushing
  • photosensitivity reaction
  • pruritus
  • sweating
  • urticaria
  • blurred vision
  • ocular pain
  • burning sensation
  • conjunctivitis
  • visual impairment
  • taste disorder
  • tinnitus
  • erectile dysfunction
  • nocturia
  • polyuria
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • sialadenitis
  • convulsions
  • gastrointestinal irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • pneumonia
  • pulmonary edema
  • hyperglycemia
  • diabetes
  • muscle spasms
  • restlessness
  • renal failure
  • renal impairment
  • interstitial nephritis
  • mucous membrane syndrome
  • erythema multiforme
  • toxic epidermal necrolysis
  • temporary blurred vision
  • xanthopsia
  • acute myopia
  • acute angle-closure glaucoma
  • thrombocytopenia
  • vasculitis
  • anaphylactic reaction
  • hepatitis
  • dry cough
  • erythroderma
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a container that does not allow light in. Additionally, for safe storage, it is recommended to keep it at room temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Yellow oval film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.